Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.

Future oncology (London, England) - 1 Jan 2020

Martorana Federica, Vigneri Paolo, Manzella Livia, Tirrò Elena, Soto Parra Héctor J

Abstract excerpt

Due to its low incidence, liposarcoma displays a limited number of therapeutic options. However, eribulin recently received approval for the treatment of advanced liposarcoma patients, progressing to at least two chemotherapy lines. We report herein the case of a man initially diagnosed with a leyomiosarcoma, subsequently reclassified as a dedifferentiated liposarcoma, who received eribulin after he failed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Delayed Diagnosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diagnostic Errors

Share to Furans

Share to Ketones

Share to Leiomyosarcoma

Share to Retreatment

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 31916463
DOI: 10.2217/fon-2019-0596

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.PMID 31916463Read ↗

Postoperative chemotherapy with Eribulin following potentially curative surgery in patients with localized liposarcoma – a retrospective single center experienceSemantic proximity Read ↗

Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.Semantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingSemantic proximity Read ↗

Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.Semantic proximity Read ↗

Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II StudiesSemantic proximity Read ↗

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer AgentsSemantic proximity Read ↗

PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates.Semantic proximity Read ↗

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II StudySemantic proximity Read ↗

Identification and characterization of the human leiomyoma side population as putative tumor-initiating cellsSemantic proximity Read ↗

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Semantic proximity Read ↗

Establishment and characterization of a novel lymphangiosarcoma cell line (MO-LAS) compared with the hemangiosarcoma cell line (ISO-HAS).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.